Nordic life sciences investment company Karolinska Development has appointed Viktor Drvota as Chief Executive Officer, replacing, Jim Van heusden. In addition, Bo Jesper Hansen, Chair of the Board, will not stand for re-election at the 2017 Annual General Meeting.
Bo Jesper Hansen was appointed as Chair in 2013. Under his chairship, he initiated the successful transformation of Karolinska Development from a wide-ranging collection of early stage science-driven projects into a highly focused investment company with a portfolio of business-driven companies capable of delivering significant shareholder value.
Viktor Drvota is currently Karolinska’s Deputy CEO and Chief Investment Officer. He has more than 15 years of life science investment experience.
Drvota joined Karolinska Development as Chief Investment Officer in February 2016 and was promoted Deputy Chief Executive Officer in March 2017.
Prior to joining Karolinska Development he worked at SEB Venture Capital, where he was Head of Life Science from 2002 and a senior investment manager.
Before joining SEB, Drvota was a practicing cardiologist at Huddinge University Hospital in Stockholm. He has been an Associate Professor in Cardiology at Karolinska Institutet, Stockholm, since 2002.